Robeco Institutional Asset Management B.V. Has $1.29 Million Holdings in Pacira BioSciences, Inc. $PCRX

Robeco Institutional Asset Management B.V. cut its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 34.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 54,005 shares of the company's stock after selling 28,689 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 0.12% of Pacira BioSciences worth $1,291,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in PCRX. Caitong International Asset Management Co. Ltd acquired a new position in Pacira BioSciences in the first quarter valued at about $51,000. US Bancorp DE grew its stake in Pacira BioSciences by 31.0% in the first quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after acquiring an additional 537 shares during the period. Brooklyn Investment Group grew its stake in Pacira BioSciences by 372.2% in the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock valued at $56,000 after acquiring an additional 1,764 shares during the period. Wealthquest Corp acquired a new position in Pacira BioSciences in the first quarter valued at about $59,000. Finally, Strs Ohio acquired a new position in Pacira BioSciences in the first quarter valued at about $75,000. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Stock Performance

PCRX opened at $23.62 on Wednesday. Pacira BioSciences, Inc. has a 52-week low of $15.16 and a 52-week high of $27.64. The firm has a market capitalization of $1.06 billion, a PE ratio of -8.50 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.91 and a current ratio of 2.38. The business's 50-day simple moving average is $25.35 and its 200 day simple moving average is $24.88.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.74 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.01. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.The business had revenue of $181.10 million for the quarter, compared to analyst estimates of $183.11 million. During the same quarter in the prior year, the company posted $0.96 earnings per share. Pacira BioSciences's revenue was up 1.7% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Pacira BioSciences, Inc. will post 2.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on PCRX shares. Truist Financial raised Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 target price for the company in a research note on Friday, July 25th. Weiss Ratings reissued a "sell (d)" rating on shares of Pacira BioSciences in a research note on Saturday, September 27th. Finally, Zacks Research raised Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pacira BioSciences presently has an average rating of "Hold" and an average price target of $33.40.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, Director Marcelo Bigal sold 4,912 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total value of $116,267.04. Following the sale, the director owned 11,393 shares in the company, valued at $269,672.31. This represents a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.40% of the stock is owned by corporate insiders.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.